我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

基于网络药理学探讨杜仲-续断药对治疗腰椎间盘突出症的作用机制*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2019年06期
页码:
63-71
栏目:
方药研究
出版日期:
2020-06-15

文章信息/Info

Title:
Study on the Mechanism of Duzhong and Xuduan in Treating Lumbar Disc Herniation Based on Network Pharmacology
文章编号:
1000-2723(2019)06-0063-09
作者:
李志超1李丹丹1薛海鹏2徐展望2△
(1.山东中医药大学第一临床医学院,山东 济南 250355;2. 山东中医药大学附属医院脊柱骨科,山东 济南 250355)
Author(s):
LI Zhichao1 LI Dandan1 XUE Haipeng2 XU Zhanwang2
(1. The First Medical Clinical College, Shandong University of Traditional Chinese Medicine, Jinan 250355, China;2. Department of Spine & Orthopedics, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250355, China)
关键词:
杜仲-续断网络药理学腰椎间盘突出症机制
Keywords:
Duzhong and Xuduan Network Pharmacology lumbar disc herniation Mechanism
分类号:
R285.5
DOI:
10.19288/j.cnki.issn.1000-2723.2019.06.011
文献标识码:
A
摘要:
目的利用网络药理学的方法探讨杜仲-续断药对治疗腰椎间盘突出症的作用机制。方法 运用TCMSP网络数据库对杜仲-续断2味中药的主要有效成分及作用靶点进行筛选和挖掘,利用Cytoscape3.7.2软件,构建中药成分-靶点网络图;以 GeneCards 及 OMIM 在线分析平台挖掘腰椎间盘突出症的相关作用靶点,基于STRING数据库构建杜仲-续断治疗腰椎间盘突出症的蛋白互作网络图(PPI),然后进行拓扑分析,筛选出杜仲-续断治疗腰椎间盘突出症的核心靶点,利用 David 数据库对药物-疾病交集靶点进行生物通路及富集分析。结果 杜仲-续断药对成分-靶点网络图包含36个有效成分,相对应靶点1 785个;腰椎间盘突出症相关靶点366个。其中β-谷甾醇、槲皮素和山柰酚可能是杜仲-续断药对治疗腰椎间盘突出症的关键成分。核心靶点涉及 PTGS2、MMP3、TNF、IL-6、IL-1B等20个。KEGG通路富集分析提示这些靶点参与TNF信号通路、HIF-1信号通路等23条通路。结论 杜仲-续断药对中的β-谷甾醇、槲皮素和山奈酚等有效成分可能通过IL-6、IL-1B、TNF、MMP3、PTGS2等靶点作用于HIF-1信号通路、TNF信号通路,发挥治疗腰椎间盘突出症的作用,为进一步分子生物学验证和临床应用提供了理论基础。
Abstract:
Objective To explore the mechanism of Duzhong and Xuduan on the treatment of lumbar disc herniation by network pharmacology. Methods TCMSP network database was used to screen and mine the main effective components and targets of Duzhong and Xuduan, and Cytoscape3.7.2 software was used to construct the network diagram of traditional Chinese medicine components and targets. The GeneCards and OMIM online analysis platform were used to excavate the relevant action targets of lumbar disc herniation. Based on STRING database, the protein interaction network map (PPI) of eucommia bark-dipsacus asperoides was constructed, then topological analysis was carried out to screen out the core targets of eucommia bark-dipsacus asperoides. David database was used to analyze biological pathways and enrichment of drug-disease intersection targets. Results Duzhong and Xuduan component-target network diagram contains 36 active components, corresponding to 1 785 targets. There are 366 targets related to lumbar disc herniation, among them β-sitosterol, quercetin and kaempferol may be the key components of Duzhong and Xuduan in the treatment of lumbar disc herniation. The core targets more than 20 including PTGS2, MMP3, TNF, IL6 and IL1B. The enrichment analysis of KEGG pathway indicated that these targets participate in 23 pathways such as TNF and HIF-1 signal pathway. Conclusion Effective components such as β-sitosterol, quercetin and kaempferol in Duzhong and Xuduan are likely to act on HIF-1 and TNF signal pathway through IL-6, IL-1B, TNF, MMP3, PTGS2 thus playing important role in treating lumbar disc herniation, which provides a theoretical basis for further molecular biological and clinical study.

参考文献/References

[1] 陈孝平,汪建平,秦新裕,等. 外科学[M]. 北京:人民卫生出版社,2013:753.
[2] 李妍,姚啸生. 中西医治疗腰椎间盘突出症研究概况[J]. 辽宁中医药大学学报,2016,18(4):231-234.
[3] 冯晗,周宏灏,欧阳冬生. 杜仲的化学成分及药理作用研究进展[J]. 中国临床药理学与治疗学,2015,20(6):713-720.
[4] 彭红梅,李小姝. 杜仲的药理研究现状及应用展望[J]. 中医学报,2013,28(1):72-73.
[5] 李广润,宫丽丽,吕亚丽,等. 川续断皂苷Ⅵ药理作用研究进展[J]. 中国新药与临床杂志,2014,33(7):477-480.
[6] 阮朝阳. 寒湿型和寒湿兼肾虚型腰椎间盘突出症中成药用药规律分析[J]. 中国中医骨伤科杂志,2015,23(3):36-40.
[7] 肖亚平,曾杰,焦琳娜,等. 补肾中药对骨质疏松症的治疗及其信号通路调节作用的研究进展[J]. 中国中药杂志,2018,43(1):21-30.
[8] 任建敏. 食物中植物甾醇生理活性及药理作用研究进展[J]. 食品工业科技,2015,36(22):389-393.
[9] JCHOI J N,CHOI Y H,LEE J M,et al. Anti-inflammatory effects of β-sitosterol-β-D-glucoside from trachelospermum jasminoides(Apocynaceae)in lipopolysaccharide-stimulated RAW 264. 7murine macrophages[J]. Nat Prod Res,2012,26(24):2340-2343.
[10] 周海玥,汤威,姜婧,等. β-谷甾醇与豆甾醇对非酒精性脂肪肝作用的体外研究[J]. 营养学报,2016,38(5):456-461.
[11] 骆明旭,罗丹,赵万红. 槲皮素药理作用研究进展[J]. 中国民族民间医药,2014,23(17):12-14.
[12] 胡庆华,缪明星,卢国,等. 槲皮素对尿酸性肾病大鼠肾脏NLRP3和TLRs表达的影响[J]. 中草药,2013,44(24):3496-3502.
[13] 袁小亮,李林福,施伟梅,等. 槲皮素对关节软骨中MMP-13、TIMP-1表达的影响[J]. 时珍国医国药,2016,27(2):283-285.
[14] 陈育华,周克元,袁汉尧. 山奈酚药效的研究进展[J]. 广东医学,2010,31(8):1064-1066.
[15] ZHUANG Z,YE G,HUANG B. Kaempferol alleviates the interleu-kin-1β induced inflammation in rat osteoarthritis chondrocytes via Suppression of NF-κB[J]. Med Sci Monit,2017,23:3925-3931.
[16] 汤利华,方超,王浩然,等. 山奈酚对高糖诱导的糖尿病肾病大鼠肾功能和组织病理损伤的保护作用[J]. 免疫学杂志,2018,34(12):1041-1046.
[17] 杜伟,申勇,李宝俊,等. 细胞因子IL-1a、IL-6、TNF-a、MMP3与颈椎间盘退变机制的相关性研究[J]. 中国矫形外科杂志,2012,20(3):259-262.
[18] YANG C C,LIN C Y,WANG H S,et al. Matrix Metalloproteases and Tissue Inhibitors of Metalloproteinases in Medial Plica and Pannus-like Tissue Contribute to Knee Osteoarthritis Progression[J]. PloS One,2013,8(11):e79662.
[19] 杨圣,史可中,安荣泽,等. 基质金属蛋白酶-3在突出椎间盘中的表达及其意义[J]. 中国矫形外科杂志,2000(11):62-64.
[20] TAKADA T,NISHIDA K,DOITA M,et al. Interleukin-6 production is upregulated by interaction between disc tissue and macrophages[J]. Spine,2004,29(10):1089-1092.
[21] GENEVAY S,FINCKH A,PAYER M,et al. Elevated levels of tumor necrosis factor -alpha in periradicular fat tissue in patients with radiculopathy from herniateddisc[J]. Spine,2008,33(19):2041-2046.
[22] MILLWARD-SADLER S J,COSTELLO P W,FREEMONT A J,et al. Regulation of catabolic gene expression in normal and degenerate human intervertebral disc cells:implications for the pathogenesis of intervertebral disc degeneration[J]. Arthritis Res Ther,2009,11(3):R65.
[23] 于维汉,何耀华. 槲皮素在治疗骨关节炎中作用机制的研究进展[J]. 中华骨与关节外科杂志,2019,12(6):477-480.
[24] 王洁,卞莹莹,张川,等. 肿瘤坏死因子及其受体在类风湿性关节炎中的研究进展[J]. 药学实践杂志,2017,35(4):289-293.
[25] PAULISSEN S M,VAN HAMBURG J P,DAVELAAR N,et al. Synovial fibroblasts directly induce Th17 patho-genicity via the cyclooxygenase/prostaglandin E2 pathway,independent of IL-23[J]. J Immunol,2013,191(3):1364-1372.
[26] 张丹,任利玲. 缺氧诱导因子1α在组织工程成骨和成血管中的作用[J]. 中国修复重建外科杂志,2016,30(4):504-508.
[27] 黄蓓,汪庆童,刘亢亢,等. 类风湿关节炎发生发展中TNF-α信号通路与CD4~+T细胞的关系[J]. 中国药理学通报,2013,29(7):900-903.

备注/Memo

备注/Memo:
收稿日期: 2019 -11- 06
* 基金项目: 曹贻训全国名老中医传承工作室(国中医药人教函[2018]134号)
第一作者简介: 李志超(1995-),男,在读硕士研究生,研究方向:脊柱退行性疾病。
△通信作者: 徐展望,E-mail:xzw6001@163.com
更新日期/Last Update: 2020-06-30